

VIA EXPRESS MAIL

"Express Mail" mailing label number EL22732/874US

Date of Deposit February 13, 2001

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Commissioner of Patents and Trademarks, Washington, D.C. 20231.

  
Annette Crossan

LUD-5531.1 (09885374)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Van der Bruggen et al.

Serial No. : Divisional of 09/012,818

Filed : Herewith

For : ISOLATED POLYPEPTIDES WHICH BIND TO HLA-A29 MOLECULES,  
NUCLEIC ACID AND MOLECULES ENCODING THESE, AND USES  
THEREOF

Group Art Unit: to be assigned

Examiner : to be assigned

February 13, 2001

Hon. Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

**PRELIMINARY AMENDMENT**

Sir:

Prior to examination, please amend this application as follows:

**IN THE TITLE**

Cancel the current title and replace with Isolated Nucleic Acid Molecules Which Encode GAGE Genes And Uses Thereof.

**IN THE SPECIFICATION**

Page 1, line 2: after “is” add -- a divisional of Serial No. 09/012,818, filed January 23, 1998, now abandoned which is

Page 4, line 10: after “1993” add -- now U.S. Patent No. 5,558,995 --

Page 4, line 14: after “1992” add -- now abandoned --

Page 4, line 18: after “1993” add -- now U.S. Patent No. 5,620,886 --

Page 4, line 23: after “1993” add -- now U.S. Patent No. 5,571,711 --

Page 5, line 12: change “Xaa Trp” to -- Xaa Xaa Trp --

Page 5, line 14-15: delete from “and” through “residue”

Page 7, line 16: change “HEPES” to -- Hepes --

Page 10, line 13: change “peDNAI-Amp” to --pcDNAI/Amp--

Page 10, line 14: change “protocol” to -- protocols --

Page 12, line 9: change “PCT” to --PCR--

Page 16, line 5: change “amp” to --Amp I--

Page 16, line 9: change “AMP” to --Amp--

Page 16, line 14: change “follow” to --followed--

Page 20, line 15: after “4” add --,--

Page 26, line 3: change “Solte” to --Site--

Page 33, line 7: after “25” add --,--

**IN THE FIGURES**

Amend Figure 8 as indicated in the attachment.

**IN THE CLAIMS**

Cancel claims 1-22 without prejudice

Add claims 23-31 which follow.

Claim 23: An isolated nucleic acid molecule which encodes a GAGE tumor rejection antigen precursor, the amino acid sequence of which is set forth in SEQ ID NO: 27, 28, 29, 30 or 31.

Claim 24: The isolated nucleic acid molecule of claim 23, having the nucleotide sequence set forth in SEQ ID NO: 2, 3, 4, 5 or 6.

Claim 25: Expression vector useful in producing a GAGE tumor rejection antigen, comprising the isolated nucleic acid molecule of claim 23, operably linked to a promoter.

Claim 26: Isolated cell, transformed or transfected with the isolated nucleic acid molecule of claim 23.

Claim 27: Isolated cell, transformed or transfected with the expression vector of claim 25.

Claim 28: The expression vector of claim 25, further comprising a nucleic acid molecule which encodes an HLA molecule.

Claim 29: The expression vector of claim 28, wherein said HLA molecule is HLA-Cw6 or HLA-A29.

Claim 30: Kit useful in transfecting or transforming a cell comprising:

(i) the isolated nucleic acid molecule of claim 23, and

(ii) an isolated nucleic acid molecule which encodes an HLA molecule.

Claim 31: The kit of claim 30, wherein said HLA molecule is HLA-Cw6 or HLA-A29.

### **IN THE ABSTRACT**

Cancel the current abstract and replace with the following:


-- The invention relates to nucleic acid molecules which encode members of the GAGE family of tumor rejection antigen precursors and their use --

**REMARKS**

Amendments presented in the parent application have been incorporated herein. New claims 23-31 are supported by the specification. Entry of the amendment is requested.

Respectfully submitted,

FULBRIGHT & JAWORSKI, L.L.P.

By   
Norman D. Hanson  
Reg. No. 30,946

666 Fifth Avenue  
New York, New York 10102  
(212) 318-3000